Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
...

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Associated Therapies: -

Clinical Trials

Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy

Not Applicable

Terminated

Conditions: Clostridium Difficile
Prostate Cancer
Urinary Tract Infection

Interventions: Drug: Ciprofloxacin

First Posted Date: 2014-09-25

Last Posted Date: 2017-04-17

Lead Sponsor: University of Rochester

Target Recruit Count: 175

Registration Number: NCT02247960

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics

Not Applicable

Completed

Conditions: Bacterial Resistance

Interventions: Drug: Standard Aseptic Technique
Drug: Ciprofloxacin

First Posted Date: 2014-08-22

Last Posted Date: 2017-11-07

Lead Sponsor: Loma Linda University

Target Recruit Count: 120

Registration Number: NCT02223338

Locations: 🇺🇸
Loma Linda University of Health Sciences Faculty Medical Offices, Loma Linda, California, United States

REaCT Integrated Consent Model to Compare Two Standard of Care Regimens

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Ciprofloxacin
Drug: G-CSF

First Posted Date: 2014-06-24

Last Posted Date: 2017-11-06

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 142

Registration Number: NCT02173262

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada

Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects

Phase 1

Completed

Conditions: Non-smokers
Healthy Volunteers

Interventions: Drug: Pracinostat
Drug: Itraconazole
Drug: Ciprofloxacin

First Posted Date: 2014-04-21

Last Posted Date: 2017-02-23

Lead Sponsor: Helsinn Healthcare SA

Target Recruit Count: 32

Registration Number: NCT02118909

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study to Investigate the Phototoxic Potential of Faldaprevir

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Faldaprevir high dose
Drug: Faldaprevir low dose
Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2014-04-15

Last Posted Date: 2014-06-25

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02114671

Locations: 🇬🇧
1241.42.44001 Boehringer Ingelheim Investigational Site, Edinburgh, United Kingdom

BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent

Phase 3

Completed

Conditions: HIV
Benign Lymphoepithelial Lesion
Salivary Gland Disease

Interventions: Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2014-02-21

Last Posted Date: 2019-07-11

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 17

Registration Number: NCT02068846

Locations: 🇺🇸
The University of North Carolina School of Dentistry, Chapel Hill, North Carolina, United States

Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers

Phase 1

Terminated

Conditions: Diabetic Foot Ulcers

Interventions: Drug: Gentamicin Topical Gel
Drug: Ciprofloxacin
Drug: Doxycycline

First Posted Date: 2014-01-15

Last Posted Date: 2015-05-14

Lead Sponsor: Royer Biomedical, Inc.

Target Recruit Count: 9

Registration Number: NCT02036528

Locations: 🇺🇸
GF Professional Research, Corp., Miami Lakes, Florida, United States
🇺🇸
Florida Medical Center & Research, Inc., Miami, Florida, United States
🇺🇸
Detroit Clinical Research Center, PC, Farmington Hills, Michigan, United States

and more 4 locations